Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuromuscular
At what point do you consider weaning steroids or immuno-modulating agents in patients with Myasthenia Gravis?
How long do you monitor for clinical stability?
Related Questions
Which non-pharmacologic treatments for neuropathic pain have you found most effective?
What is your approach to managing seronegative myasthenia gravis in patients who have not responded to immunotherapy?
How do you approach weaning treatments for CIDP in remission?
When do you obtain nerve biopsy to evaluate for vasculitic neuropathy in patients with distal symmetric polyneuropathies?
What types of cardiac conduction abnormalities would lead you to avoid using tricyclic antidepressants?
How do you counsel patients on the benefits of immunotherapy for anti-MAG neuropathy?
What treatments, after appropriate dose reductions/delays, do you offer for patients with oxaliplatin-induced cold allodynia/dysesthesia?
How do you counsel patients with postural orthostatic tachycardia syndrome (POTS) regarding safe and effective exercise regimens?
How do you counsel patients and doctors on antibiotic avoidance in myasthenia gravis?
Should IVIG dosing in patients with autoimmune disease (i.e., dermatomyositis) who become pregnant continue to be based on actual weight at the time of each infusion, or should it be limited to pre-pregnancy weight?